Ikena Oncology (NASDAQ:IKNA) Earns “Neutral” Rating from Wedbush

Wedbush reissued their neutral rating on shares of Ikena Oncology (NASDAQ:IKNA) in a research report sent to investors on Thursday,RTT News reports. They currently have a $2.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Ikena Oncology in a research note on Monday, August 12th.

Ikena Oncology Price Performance

Ikena Oncology stock traded up $0.01 during mid-day trading on Thursday, reaching $1.70. 25,377 shares of the company traded hands, compared to its average volume of 246,568. The firm’s fifty day moving average is $1.70 and its two-hundred day moving average is $1.63. Ikena Oncology has a fifty-two week low of $1.02 and a fifty-two week high of $3.92. The company has a market capitalization of $82.04 million, a price-to-earnings ratio of -1.18 and a beta of 0.48.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. As a group, equities research analysts predict that Ikena Oncology will post -1.03 earnings per share for the current year.

Institutional Trading of Ikena Oncology

Several institutional investors and hedge funds have recently modified their holdings of IKNA. Vanguard Personalized Indexing Management LLC purchased a new position in Ikena Oncology during the second quarter worth approximately $30,000. BBR Partners LLC acquired a new position in Ikena Oncology during the 2nd quarter worth $33,000. AQR Capital Management LLC acquired a new position in Ikena Oncology during the 2nd quarter worth $36,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ikena Oncology in the 2nd quarter worth about $75,000. Finally, JBF Capital Inc. bought a new position in shares of Ikena Oncology in the 2nd quarter worth about $120,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.